Medikit Q1 Operating Profit Rises 24% on Catheters and Intervention Devices

Growth in all three product lines

Medikit Co., Ltd. (TSE: 7749) published consolidated results for the three months to June 30, 2026 on August 7, 2026 under Japanese GAAP. Net sales rose 8.1% to ¥6,365 million, operating profit 23.8% to ¥1,266 million, ordinary profit 21.7% to ¥1,300 million and net profit attributable to owners of the parent 33.5% to ¥523 million, for earnings per share of ¥36.15 against ¥26.83.

Medikit reports a single segment — medical devices — so the detail is by product line. IV catheters were the largest at ¥2,247 million (+9.7%), followed by dialysis-related products at ¥2,087 million (+6.6%) and intervention devices at ¥2,020 million (+7.6%). The three are within ¥230 million of each other — an unusually even split, and one that leaves the company less exposed to any single line.

Margin, and a figure the company presents separately

The operating margin widened to 19.9% from 17.4% — profit growing at nearly three times the rate of sales. The company also presents operating profit before goodwill amortisation, at ¥1,320 million against ¥1,077 million (+22.6%). The ¥54 million gap between that and reported operating profit is the quarter's goodwill amortisation charge; the growth rates on the two measures are close, so the amortisation is not what is driving the improvement.

Named products across the three lines include the Happy Cath ProFlex and Super Cath 5 / Super Cath 7 IV catheter ranges, the AbRoad STOUT and AbRoad FLEX intervention devices, and the Medilizer AGD.

A balance sheet with almost no debt

Total assets edged down 0.8% from the March year-end to ¥52,855 million and net assets 0.3% to ¥46,645 million, so the equity ratio rose to 88.3% from 87.8%. At 88% equity this is among the least leveraged balance sheets on the exchange, and the reason a company of Medikit's size can absorb an acquisition without strain. Comprehensive income was ¥588 million against ¥303 million.

Guidance unchanged — and it implies a slowdown

Guidance for FY3/2027, set on May 15, 2026, is unchanged: net sales of ¥25,800 million (+8.5%), operating profit of ¥4,300 million (+0.6%), ordinary profit of ¥4,400 million (−1.9%) and net profit of ¥2,850 million (−5.2%), for earnings per share of ¥196.85. First-half targets are ¥12,400 million, ¥2,100 million, ¥2,150 million and ¥1,200 million respectively.

The gap between the quarter and the year is worth stating plainly. Operating profit grew 23.8% in the first three months, but the full-year target implies +0.6% — meaning the company expects essentially no operating-profit growth across the remaining nine months, and a decline at the ordinary and net lines. Guidance was left unchanged rather than raised. Sales growth is the one line where the quarter (+8.1%) and the year (+8.5%) agree, so the implied slowdown is entirely on costs.

One subsequent event: the consolidation of T.G. Medical, Inc. was announced on July 3, 2026. The company states the impact on FY3/2027 results is immaterial. The annual dividend forecast is unchanged at ¥100.00 per share, split ¥50.00 interim and ¥50.00 year-end.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.